8-pCPT-2'-O-Me-cAMP-AM

8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway. In Vitro 8-pCPT-2'-O-Me-cAMP-AM (2.5 μM; 30 min) activates Epac and prevents adherens junction disassembly during hypoxia (60 min). 8-pCPT-2'-O-Me-cAMP-AM can cross the plasma membrane and is able to alter diverse cellular functions that include Rap1 GTPase activity, PKB, and ERK1/2 protein kinase activity, phospholipase C activity, Ca 2+ signaling, ion channel activity, exocytosis, cell adhesion, and gene expression. 8-pCPT-2'-O-Me-cAMP-AM stimulates insulin secretion with dose-dependent and glucose metabolism-dependent (0.1 or 1.11 mM) actions. 8-pCPT-2'-O-Me-cAMP-AM (20 μM) activates the cAMP reporter Epac1-camps, while 8-pCPT-2'-O-Me-cAMP doesn’t in INS-1 cells. 8-pCPT-2'-O-Me-cAMP-AM (0.3-3.0 μM; 0-300 sec) activates Epac1-camps in a dose- and time-dependent manner in high throughput assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo 8-pCPT-2'-O-Me-cAMP-AM (intrarenal injection; ) activates renal Rap1 and likely is caused by activation of Epac in the tubular epithelium . 8-pCPT-2'-O-Me-cAMP-AM preserves renal function by Epac activation and reduces tubular epithelial-cell stress during ischemia . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: IR injuried mouse model Dosage: 1.45 mM Administration: Intrarenal injection; mice were sacrificed at 24, 48, or 72 hours after ischemia Result: Protected renal injury during ischemia. Form:Oil

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet